Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 3:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 208 matching trials from the live ClinicalTrials.gov search.
Filters: "early Parkinson" Condition: Parkinson's Disease Clear all
Completed No phase listed Observational Accepts healthy volunteers

Electromyography Signals as Biomarkers for Parkinson's Disease

NCT02168504
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Not listed
Lead sponsor
Norconnect Inc
Industry
Eligibility
25 Years to 82 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Ogdensburg, New York
Source: ClinicalTrials.gov public record
Updated Oct 8, 2015 · Synced Oct 9, 2026, 3:15 AM EDT
Completed Phase 2 Interventional

National Institute of Neurological Disorders and Stroke (NINDS) Parkinson's Disease Neuroprotection Trial

NCT00063193
View directory record Official record
Conditions
Parkinson's Disease
Interventions
minocycline, creatine
Drug
Lead sponsor
University of Rochester
Other
Eligibility
30 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Oct 9, 2026, 3:15 AM EDT
Completed Phase 1 Interventional

A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Opicapone in Subjects With Parkinson's Disease Taking Levodopa.

NCT03496870
View directory record Official record
Conditions
Parkinson Disease
Interventions
Opicapone, Carbidopa Levodopa
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
3
States / cities
Glendale, California • Long Beach, California • Farmington Hills, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 22, 2019 · Synced Oct 9, 2026, 3:15 AM EDT
Completed Phase 1 Interventional

Pilot Study To Assess Effect of Treatment and Adherence in PD Subjects

NCT01788696
View directory record Official record
Conditions
Parkinson Disease
Interventions
Group A - Early Imaging, Group B - Delayed Imaging
Radiation
Lead sponsor
Duke University
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 12, 2015 · Synced Oct 9, 2026, 3:15 AM EDT
Completed Phase 1 Interventional

Study of IRX4204 for Treatment of Early Parkinson's Disease

NCT02438215
View directory record Official record
Conditions
Parkinson's Disease
Interventions
IRX4204
Drug
Lead sponsor
Io Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 12, 2015 · Synced Oct 9, 2026, 3:15 AM EDT
Completed No phase listed Observational

The GBA Multimodal Study in Parkinson's Disease

NCT04101968
View directory record Official record
Conditions
Parkinson Disease, GBA Gene Mutation, Gaucher Disease
Interventions
PET scan, neuroQWERTY
Diagnostic Test
Lead sponsor
Pacific Parkinson's Research Centre
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
2
States / cities
Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 9, 2026, 3:15 AM EDT
Completed Phase 2 Interventional

Study of Individuals With Parkinson's Symptoms But in Whom There is Diagnostic Uncertainty

NCT00129675
View directory record Official record
Conditions
Parkinsonian Syndrome
Interventions
[123I]ß CIT
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
21 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 16, 2014 · Synced Oct 9, 2026, 3:15 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cell Studies of Parkinson's Disease

NCT00076505
View directory record Official record
Conditions
Parkinson Disease
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 9, 2026, 3:15 AM EDT
Completed Phase 2 Interventional Results available

Nilotinib in Parkinson's Disease

NCT03205488
View directory record Official record
Conditions
Parkinson Disease
Interventions
Cohort 1:Nilotinib Oral Capsules (150mg or 300mg), Cohort 2: Nilotinib Oral Capsules (dose to be determined from Cohort 1), Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
40 Years to 79 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
24
States / cities
Birmingham, Alabama • Sun City, Arizona • Sacramento, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2020 · Synced Oct 9, 2026, 3:15 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Parkinson's Disease Biomarkers in Nerve Cells in the Gut

NCT05347407
View directory record Official record
Conditions
Parkinson Disease
Interventions
Colonoscopy
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
45 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 9, 2026, 3:15 AM EDT
Completed Phase 2 Interventional Results available

Modafinil for Freezing of Gait (FOG) in Parkinson's Disease (PD)

NCT03083132
View directory record Official record
Conditions
Parkinson Disease
Interventions
modafinil 50mg, Placebo oral capsule
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
50 Years to 90 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Oct 9, 2026, 3:15 AM EDT
Terminated Phase 2 Interventional Results available

PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706

NCT03655236
View directory record Official record
Conditions
Early Parkinson Disease
Interventions
K0706, placebo
Drug · Other
Lead sponsor
Sun Pharma Advanced Research Company Limited
Industry
Eligibility
50 Years and older
Enrollment
513 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
34
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2025 · Synced Oct 9, 2026, 3:15 AM EDT
Completed No phase listed Observational

Hereditary Parkinson s Disease Natural History Protocol

NCT02511015
View directory record Official record
Conditions
Parkinson Disease 6, Early-Onset, Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human, Parkinson Disease Autosomal Recessive, Early Onset, Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 9, 2026, 3:15 AM EDT
Completed Phase 3 Interventional

An Open Label SLV308 Safety Extension to Study S308.3.001 in Early PD Patients

NCT00332917
View directory record Official record
Conditions
Early Stage Parkinson's Disease
Interventions
Pardoprunox
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
30 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
25
States / cities
Huntsville, Alabama • Little Rock, Arkansas • Fountain Valley, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2009 · Synced Oct 9, 2026, 3:15 AM EDT
Not yet recruiting Not applicable Interventional

VC/VS for Apathy in PD

NCT06991335
View directory record Official record
Conditions
Parkinson Disease, Deep Brain Stimulation, Apathy
Interventions
Deep Brain Stimulation
Device
Lead sponsor
Nora Vanegas
Other
Eligibility
40 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Oct 9, 2026, 3:15 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effect of Stimulus Rate on Cognitive and Motor Activity in Young Subjects, Elderly Subjects, and Patients With Parkinson's Disease

NCT00026598
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 9, 2026, 3:15 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

The University of Alabama at Birmingham (UAB) Neuroinflammation in Parkinson's Disease-TSPO- Positron Emission Tomography (PET) Substudy

NCT03457493
View directory record Official record
Conditions
Parkinson Disease
Interventions
DPA-714-PET/MRI, 5-year Follow-up DPA-714-PET/MRI, DPA-714 Metabolite Analysis
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
30 Years and older
Enrollment
205 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 9, 2026, 3:15 AM EDT
Not listed No phase listed Observational

Microbiome Composition and Function Contributes to Cognitive Impairment and Neuroinflammation in Parkinson's Disease

NCT05419453
View directory record Official record
Conditions
Parkinson Disease
Interventions
Not listed
Lead sponsor
California State University, San Bernardino
Other
Eligibility
55 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
San Bernardino, California
Source: ClinicalTrials.gov public record
Updated Feb 8, 2024 · Synced Oct 9, 2026, 3:15 AM EDT
Completed Phase 3 Interventional Results available

An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s Disease

NCT00632736
View directory record Official record
Conditions
Parkinson Disease, Parkinson's Disease
Interventions
Ropinirole XL (formerly CR)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years and older
Enrollment
419 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
25
States / cities
Birmingham, Alabama • Fountain Valley, California • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Oct 9, 2026, 3:15 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor Fluctuations

NCT03670953
View directory record Official record
Conditions
Parkinson's Disease (Disorder)
Interventions
IR CD-LD, IPX203 ER CD-LD, Placebo Matching IPX203, Placebo Matching IR CD-LD
Drug · Other
Lead sponsor
Impax Laboratories, LLC
Industry
Eligibility
40 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
56
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Loma Linda, California + 46 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Oct 9, 2026, 3:15 AM EDT
Completed Phase 2 Interventional Results available

Safety of Urate Elevation in Parkinson's Disease

NCT00833690
View directory record Official record
Conditions
Parkinson Disease
Interventions
Placebo, inosine
Drug
Lead sponsor
The Parkinson Study Group
Network
Eligibility
30 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
16
States / cities
Los Angeles, California • Manchester, Connecticut • New Haven, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2014 · Synced Oct 9, 2026, 3:15 AM EDT
Completed Phase 3 Interventional Results available

A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD

NCT05357989
View directory record Official record
Conditions
Parkinson's Disease, Idiopathic
Interventions
buntanetap/posiphen, Placebo
Drug
Lead sponsor
Annovis Bio Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
523 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
43
States / cities
Birmingham, Alabama • Sun City, Arizona • Fountain Valley, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Oct 9, 2026, 3:15 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate Safety and Efficacy of KM-819 in Healthy Adults and Participants with Parkinson's Disease

NCT05670782
View directory record Official record
Conditions
Parkinson Disease
Interventions
KM-819, Placebo
Drug
Lead sponsor
FAScinate Therapeutics Inc.
Industry
Eligibility
40 Years and older
Enrollment
314 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
3
States / cities
Glendale, California • San Diego, California • Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Oct 9, 2026, 3:15 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease

NCT01968460
View directory record Official record
Conditions
Parkinson's Disease
Interventions
P2B001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg),, Placebo, P2B001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg),
Drug
Lead sponsor
Pharma Two B Ltd.
Industry
Eligibility
35 Years to 75 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
24
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2023 · Synced Oct 9, 2026, 3:15 AM EDT